Brii Biosciences Limited Stock
Stocks
2137
KYG1645A1094
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Hong Kong S.E.
11:08:52 06/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 1.040 HKD | +1.46% |
|
+6.12% | -26.24% |
| 10-16 | Brii Biosciences Launches siRNA Therapeutics Discovery Platform | MT |
| 10-15 | Brii Biosciences Limited Unveils BRiSC?, An siRNA Therapeutics Discovery Platform | CI |
| Market Cap | 639M 751M 95.75M 85.88M 78.49M 71.65M 135M 9B 139M 946M 377M 4.8B 359M 352M 15.16B | P/E 2024 |
-1.32x | P/E 2025 | -4.11x |
|---|---|---|---|---|---|
| Enterprise Value | -1.29B -1.52B -193M -173M -158M -145M -273M -18.17B -281M -1.91B -762M -9.7B -726M -710M -30.61B | EV / Sales 2024 |
-32.4x | EV / Sales 2025 | -28.6x |
| Free-Float |
93.28% | Yield 2024 * |
-
| Yield 2025 | - |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 2137 | Delayed | |
Tradegate
| 7SS | Real-time | |
|
Deutsche Boerse AG
| 7SS | Delayed | |
|
Börse Stuttgart
| 7SS | Delayed | |
|
Boerse Muenchen
| 7SS | Real-time |
Last Transcript: Brii Biosciences Limited
| 1 day | +1.46% | ||
| 1 week | +6.12% | ||
| Current month | +6.12% | ||
| 1 month | +18.18% | ||
| 3 months | +12.43% | ||
| 6 months | -22.39% | ||
| Current year | -26.24% |
| 1 week | 0.96 |  | 1.08 |
| 1 month | 0.82 | | 1.08 |
| Current year | 0.82 | | 1.7 |
| 1 year | 0.82 | | 1.9 |
| 3 years | 0.8 | | 3.5 |
| 5 years | 0.8 | | 48.65 |
| 10 years | 0.8 | | 52.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhi Hong
CEO | Chief Executive Officer | 62 | 23/02/2018 |
An Kang Li
DFI | Director of Finance/CFO | 48 | 01/09/2020 |
Brian Johns
CTO | Chief Tech/Sci/R&D Officer | - | 03/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Zhi Hong
CHM | Chairman | 62 | 24/03/2021 |
Martin Murphy
BRD | Director/Board Member | 83 | 22/06/2021 |
Hui Tang
BRD | Director/Board Member | 66 | 22/06/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/24/26 A | Other | Chief Financial Officer | -43,500 | 0.0059% | ||
| 9/21/26 A | Other | Chief Executive Officer | -24,172 | 0.0033% | ||
| 8/27/26 A | Other | Chief Financial Officer | -1,500 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.46% | +6.12% | -43.48% | -66.67% | 95.75M | |
| -4.83% | +3.51% | +53.62% | +61.75% | 65.94B | |
| -1.34% | +2.98% | +24.79% | +100.18% | 56.53B | |
| +0.02% | +1.07% | +10.63% | +76.66% | 56.88B | |
| +5.09% | +9.89% | +22.45% | +107.48% | 46.49B | |
| +2.62% | +1.68% | +28.91% | +37.01% | 44.8B | |
| +8.24% | +0.51% | +213.26% | +792.66% | 41.59B | |
| -1.86% | +10.13% | +26.82% | +53.22% | 35.35B | |
| -2.97% | -9.84% | +88.86% | +76.17% | 33.29B | |
| -2.18% | +7.06% | +36.06% | -4.95% | 24.92B | |
| Average | +0.42% | +3.54% | +46.19% | +123.35% | 40.59B | |
| Weighted average by Cap. | +0.21% | +3.40% | +53.10% | +142.91% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 49.94M 58.63M 7.48M 6.71M 6.13M 5.59M 10.54M 703M 10.87M 73.88M 29.46M 375M 28.07M 27.46M 1.18B | 35.55M 41.73M 5.32M 4.77M 4.36M 3.98M 7.5M 500M 7.74M 52.59M 20.97M 267M 19.98M 19.55M 843M |
| Net income | -508M -597M -76.09M -68.25M -62.37M -56.94M -107M -7.15B -111M -752M -300M -3.82B -286M -279M -12.05B | -223M -261M -33.34M -29.9M -27.32M -24.94M -46.99M -3.13B -48.48M -329M -131M -1.67B -125M -122M -5.28B |
| Net Debt | -2.29B -2.69B -343M -308M -281M -257M -484M -32.27B -499M -3.39B -1.35B -17.22B -1.29B -1.26B -54.35B | -1.93B -2.27B -289M -259M -237M -216M -408M -27.17B -420M -2.86B -1.14B -14.5B -1.09B -1.06B -45.77B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/11/26 | HK$1.040 | +1.46% | 884,000 |
| 05/11/26 | HK$1.025 | 0.00% | 839,000 |
| 04/11/26 | HK$1.025 | +4.59% | 1,020,000 |
| 03/11/26 | HK$0.9800 | -2.49% | 773,000 |
| 02/11/26 | HK$1.005 | +2.55% | 512,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 2137 Stock
Select your edition
All financial news and data tailored to specific country editions
